title: Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor.
abstract: The neuropeptides oxytocin (OT) and vasopressin (AVP) are recognized for their modulation of social processes in humans when delivered peripherally. However, there is surprisingly little evidence for acute social effects of peripherally administered OT or AVP in animal models. On the other hand, the party drug 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') has powerful prosocial effects in rats that appear to occur through stimulation of central OT release. Here, we directly compared the social effects of peripherally administered OT and AVP with those of MDMA, and examined a possible role for the vasopressin 1A receptor (V1AR) in the observed prosocial effects. Adult male Long-Evans rats were tested in a social interaction paradigm after OT (0.1, 0.25, 0.5, and 1 mg/kg, intraperitoneal (IP)), AVP (0.001, 0.0025, 0.005, 0.01, and 0.1 mg/kg, IP), and MDMA (2.5, 5 mg/kg, IP), or combined low doses of OT and MDMA, or AVP and MDMA. The effects of pretreatment with the non-peptide OT receptor antagonist compound 25 (C25; 5 mg/kg, IP) and the V1AR antagonist SR49059 (1 mg/kg, IP) were also examined. OT (0.5 mg/kg), AVP (0.01 mg/kg), and MDMA (5 mg/kg) potently increased 'adjacent lying', where rats meeting for the first time lie passively next to each other. C25 did not inhibit adjacent lying induced by OT, whereas SR49059 inhibited adjacent lying induced by MDMA (5 mg/kg), OT (0.5 mg/kg), and AVP (0.01 mg/kg). Interestingly, when ineffective doses of OT and MDMA, or AVP and MDMA, were combined, a robust increase in adjacent lying was observed. These results show for the first time acute prosocial effects of peripherally injected OT and AVP in laboratory rats, and suggest a commonality of action of OT, AVP, and MDMA in stimulating social behavior that involves V1ARs.
authors.affiliation: School of Psychology, University of Sydney, Sydney, NSW, Australia.
authors.forename: Linnet
authors.initials: L
authors.lastname: Ramos
authors.forename: Callum
authors.initials: C
authors.lastname: Hicks
authors.forename: Richard
authors.initials: R
authors.lastname: Kevin
authors.forename: Alex
authors.initials: A
authors.lastname: Caminer
authors.forename: Rajeshwar
authors.initials: R
authors.lastname: Narlawar
authors.forename: Michael
authors.initials: M
authors.lastname: Kassiou
authors.forename: Iain S
authors.initials: IS
authors.lastname: McGregor
mesh_terms: D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006213:Hallucinogens / Q000494:pharmacology; D006727:Hormone Antagonists / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D008297:Male; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000494:pharmacology*; D010121:Oxytocin / Q000494:pharmacology*; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D018045:Receptors, Oxytocin / Q000037:antagonists & inhibitors; D017483:Receptors, Vasopressin / Q000819:agonists*; D012919:Social Behavior; D014667:Vasopressins / Q000494:pharmacology*
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D006213:Hallucinogens; D006727:Hormone Antagonists; D007211:Indoles; D011759:Pyrrolidines; D018045:Receptors, Oxytocin; D017483:Receptors, Vasopressin; D014667:Vasopressins; D010121:Oxytocin; C082134:relcovaptan; D018817:N-Methyl-3,4-methylenedioxyamphetamine